Posted by Michael Wonder on 21 Sep 2023
Takeda receives positive CHMP opinion for Adcetris (brentuximab vedotin) for the treatment of adult patients with previously untreated CD30+ stage III Hodgkin lymphoma in combination with AVD
18 September 2023 - Takeda announced today that the CHMP of the EMA has adopted a positive opinion for the extension of the marketing authorisation of Adcetris (brentuximab vedotin) and recommended its approval in combination with doxorubicin, vinblastine and dacarbazine (AVD) in adult patients with previously untreated CD30 positive stage III Hodgkin lymphoma.
The positive CHMP opinion is based on the results of the randomised Phase 3 ECHELON-1 trial designed to compare Adcetris plus AVD to doxorubicin, bleomycin, vinblastine, and dacarbazine as a therapy in adult patients with previously untreated stage III or IV Hodgkin lymphoma.
